MarginsXMarginsX
Home › Markets › Health Care › QURE

uniQure N.V. (QURE)

QURE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$21.88
-8.11% on the day
Market cap
$1.5B
Small cap
Revenue · 2025
$16.1M
-40.6% on 2024
Net income · 2025
-$199.0M
-1236.0% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1590560/000110465926021898/0001104659-26-021898-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerQURE on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryNetherlands
IPO year2014
SEC CIK0001590560
SEC industry codePharmaceutical Preparations

Financials · 2025

LineValue
Revenue$16.1M
Net income-$199.0M
Operating income-$185.3M
Net margin-1236.0%
Operating margin-1151.4%
Revenue growth-40.6%
Cash$80.2M
Total assets$824.9M
P/E (computed)Net income was not positive
P/S (computed)95.3×

Warning signs

Cash runway
6.1 months
$98.4M cash at September 30, 2026
Share count, 1 year
+12.6%
2025-11-06 to 2026-11-02 · +46.7% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
-$21.8M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$98.4M cash; operating cash flow -$48.1M a quarter.Report 2026-09-30
Shares outstanding70,138,860 (2026-11-02); 62,291,663 a year earlier; 47,811,479 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-06-24
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorKPMG Accountants N.V., Amstelveen, NetherlandsPCAOB Form AP 2026-04-07
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $21.8M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$5.2M-$61.2M-$47.8M$98.4M$50.3M$20.2M10-Q 2026-11-04
Q2 2026
2026-06-30
$5.8M-$81.1M-$28.6M$413.0M$50.1M$18.7M10-Q 2026-07-29
Q1 2026
2026-03-31
$3.6M-$53.5M-$38.2M$140.0M$49.9M$18.1M10-Q 2026-05-05
Q4 2025
2025-12-31
$5.6M-$37.1M-$77.6M$80.2M$71.9M$16.1M10-K 2026-03-02
Q3 2025
2025-09-30
$3.7M-$80.5M-$16.4M$597.1M$51.9M$15.8M10-Q 2026-11-04
Q2 2025
2025-06-30
$5.3M-$37.7M-$39.9M$253.8M$51.8M$14.3M10-Q 2026-07-29
Q1 2025
2025-03-31
$1.6M-$43.6M-$44.1M$217.2M$51.6M$20.2M10-Q 2026-05-05
Q4 2024
2024-12-31
$5.2M-$73.3M-$52.8M$158.9M$66.0M$27.1M10-K 2026-03-02

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-06-24
Latest annual report10-K2026-03-02
Latest quarterly / interim10-Q2026-11-04
Latest current report
FORM 8-K
8-K2026-11-04
Latest proxyDEFA14A2026-04-27

Source: SEC EDGAR submissions feed, 955 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+9.7%
1 month+11.9%
3 months-49.4%
Year to date-0.5%
1 year-21.5%
From 52-week high-53.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
PGENPrecigen Inc.$4.30-5.29%$1.5B
SLSSELLAS Life Sciences Group Inc.$7.47-4.96%$1.5B
ADRXADARx Pharmaceuticals Inc.$14.00-1.41%$1.6B
KRSAKorsana Biosciences Inc.$32.68+3.25%$1.5B
RAPPRapport Therapeutics Inc.$24.82-5.09%$1.5B
NRIXNurix Therapeutics Inc.$14.73-4.84%$1.6B
PCRXPacira BioSciences Inc.$36.48+0.05%$1.5B
ANIPANI Pharmaceuticals Inc.$70.89-0.77%$1.6B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier